The prevention rate is 96%!

On July 22, at the innovation conference held in Yizhuang, Beijing, Shenzhou Cell publicly released the world's first 14-valent HPV vaccine developed by it for the first time

At the innovation conference, Tang Liming, director and deputy general manager of Shenzhou Cell, said: "From the current experimental data, this 14-valent HPV vaccine can increase the overall cervical cancer prevention rate from 90% of the 9-valent vaccine to 96%

At present, the 14-valent HPV vaccine developed by Shenzhou Cell has entered clinical phase I/II studies, and all 80 cases have been enrolled

Cervical cancer (HPV) is mainly composed of more than 200 different types.

That is to say, the higher the "valency" of the vaccine, the more types of viruses that can be prevented, and the higher the prevention rate

Currently

As women’s awareness of cervical cancer prevention has increased, these HPV vaccines currently on the market in China are all experiencing a shortage of vaccines, making it difficult to obtain a vaccine

From these perspectives, the 14-valent HPV vaccine developed by Shenzhou Cell is of great significance.